Dyslipidemia

FDA approved once-daily oral enlicitide to lower LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Catch up on FDA approvals, trial readouts, and key clinician insights across the cardiology specialty.

Leiter discusses the growth of incretin-based therapies through all aspects of the cardio-kidney-metabolic syndrome space.

Leiter discusses the importance of earlier and more dramatic lipid-lowering interventions in patients with diabetes at risk of cardiovascular disease.

Rishi Wadhera, MD, MPP, MPhil, addresses performance metrics, cross-specialty prescribing, and the policy forces reshaping the cardiometabolic care cascade.

The US FDA has approved olezarsen as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia.

Rishi Wadhera, MD, MPP, MPhil, discusses where the cardiometabolic care cascade is failing most consequentially at the 10th Annual Heart in Diabetes Meeting.

A Family Heart Database analysis found only 1.1% of US adults have undergone lipoprotein(a) testing.

Lilly reports dose-dependent PCSK9 and LDL-C reductions with single-dose VERVE-102 in interim phase 1b hypercholesterolemia data.

Catapano discusses the superior reduction in LDL-C, ApoB, and non-HDL-C demonstrated by enlicitide, suggesting its role as an add-on for LDL-C lowering.

Catch up on major trial results, groundbreaking guideline updates, and more.

March 2026 cardiology updates feature key ACC.26 data, new guidelines, and advances in PAH, AF, hypertension, and lipid management.

Navar discusses the phase 3 CORALreef AddOn trial, highlighting enlicitide’s superiority to ezetimibe, bempedoic acid, and a combination of both.

Catch up on the most impactful trial readouts to come out of ACC 2026.

Nicholls discusses his recent pooled analysis of safety data from the BROADWAY and BROOKLYN phase 3 trials, proving the tolerable safety of obicetrapib.

A subgroup analysis of VESALIUS-CV suggests evolocumab could have a role in prevention of primary events in some high-risk patients.

Bhatt shares his thoughts on the recently released dyslipidemia guidelines, highlighting the return of goal-based LDL-C therapy and Lp(a) receiving a COR 1 suggestion.

New dyslipidemia guidance sharpens risk with CAC, checks lipoprotein(a), and targets LDL goals using expanded therapies for prevention.

New dyslipidemia guidance sets LDL targets for FH, urges genetic testing, and highlights evinacumab and APOC3 drugs for severe triglycerides.

Trials show most heart supplements don’t lower LDL or prevent events; learn why omega‑3s, vitamins and red yeast rice fall short of statins.

New lipid guidelines sharpen LDL goals for diabetes, HIV, CKD, cancer survivors and seniors, highlighting statins’ power and shared decisions.

New lipid guidance brings back LDL targets by risk, pairing percent reduction with absolute goals—and explains why lower is better.

New US guidance spotlights one-time lipoprotein(a) tests and ApoB targets to uncover hidden heart risk and fine-tune lipid therapy.